尼沃卢马布在复发性或耐火性初级中枢神经系统淋巴瘤:多中心,回顾性研究
Jun Ho Yi1, Seok Jin Kim2, Sang-A Kim3
1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.
Cancer research and treatment
|August 20, 2024
概括
尼沃卢马布单一治疗对复发或耐药的中枢神经系统原发性淋巴瘤 (PCNSL) 显示出前景,有41%的患者实现了客观反应和持久的持续时间. 治疗耐受性很好,这表明它是这种具有挑战性的疾病的可行选择.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 主要中枢神经系统淋巴瘤 (PCNSL) 影响大脑,脊髓和脑膜.
- 在40-50%的PCNSL病例中异常的9p24.1基因状态表明免疫检查点抑制剂 (ICI) 的潜在有效性.
研究的目的:
- 评估尼沃卢马布单一治疗在复发或耐药PCNSL的患者中的有效性和安全性.
- 为了确定客观的应答率,无进展的存活率和这一患者队列的整体存活率.
主要方法:
- 对22名患有复发性或耐药性PCNSL的患者进行了回顾性分析,这些患者接受了尼沃卢马布单一治疗.
- 收集的数据包括患者人口统计学,治疗史,客观反应,反应持续时间,无进展生存率和整体生存率.
主要成果:
- 41%的患者实现了客观反应 (6个完整反应,3个部分反应),平均持续时间为20.9个月.
- 中位数无进展生存时间为2.1个月,中位数整体生存时间为18.9个月.
- 尼沃卢马布耐受性良好,无需降低剂量,只有两名患者需要延迟治疗.
结论:
- 尼沃卢马布单一治疗显示出作为复发性或耐火性PCNSL的治疗选择的潜力.
- 观察到的持久反应表明,尼沃卢马布可能是有限治疗选择的患者的有价值的治疗策略.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Primary Lymphoid Organs
1.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.5K
Secondary Lymphoid Organs
1.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.4K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K


